Brain Activation and Satiety in Children 2
NCT04520490 on ClinicalTrials.gov · last registry update 2026-01-05
A small phase 3 — 63 participants, against a typical 424. The sponsor logged completion for 21 August 2025. Primary outcome, as filed: Change of BMI z-score. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- Seattle Children's Hospital
- Sponsor type
- Other
- Enrollment
- 63
- Started
- 2021-01-28
- Primary completion
- 2025-08-21 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change of BMI z-score
Conditions studied
Childhood Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.